SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats

Toxicology and Applied Pharmacology

Volumn 333, Issue , 2017, Pages 43-50

  Sa nguanmoo, Piangkwan ^a   Tanajak, Pongpan ^a   Kerdphoo, Sasiwan ^a   Jaiwongkam, Thidarat ^a   Pratchayasakul, Wasana ^a   Chattipakorn, Nipon ^a,b   Chattipakorn, Siriporn C ^a,b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Cognitive function; Dapagliflozin; Mitochondrial function; Obese insulin resistance; Synaptic plasticity; Vildagliptin

Indexed keywords

CHOLESTEROL; DAPAGLIFLOZIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VILDAGLIPTIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ADAMANTANE; ANTIINFLAMMATORY AGENT; BENZHYDRYL DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSIDE; MALONALDEHYDE; NEUROPROTECTIVE AGENT; NITRILE; PYRROLIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SGLT2 PROTEIN, RAT; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD SAMPLING; BRAIN FUNCTION; BRAIN MITOCHONDRION; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DIET INDUCED OBESITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; EXCITATORY POSTSYNAPTIC POTENTIAL; GLUCOSE BLOOD LEVEL; HIPPOCAMPAL SLICE; HIPPOCAMPUS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MALE; METABOLIC PARAMETERS; MITOCHONDRIAL MEMBRANE POTENTIAL; MORRIS WATER MAZE TEST; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BRAIN; COGNITION DISORDERS; DRUG EFFECTS; MAZE TEST; MEMORY; METABOLISM; MITOCHONDRION; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ADAMANTANE; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BENZHYDRYL COMPOUNDS; BRAIN; COGNITION DISORDERS; DIET, HIGH-FAT; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCOSIDES; INSULIN; INSULIN RESISTANCE; LONG-TERM POTENTIATION; MALE; MALONDIALDEHYDE; MAZE LEARNING; MEMBRANE POTENTIAL, MITOCHONDRIAL; MEMORY; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; NITRILES; OBESITY; OXIDATIVE STRESS; PYRROLIDINES; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85027518734     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2017.08.005     Document Type: Article

References (27)

1. Bailey, C.J., Gross, J.L., Hennicken, D., Iqbal, N., Mansfield, T.A., List, J.F., Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med., 11, 2013, 43.
2. Bomfim, T.R., Forny-Germano, L., Sathler, L.B., Brito-Moreira, J., Houzel, J.C., Decker, H., Silverman, M.A., Kazi, H., Melo, H.M., McClean, P.L., Holscher, C., Arnold, S.E., Talbot, K., Klein, W.L., Munoz, D.P., Ferreira, S.T., De Felice, F.G., An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J. Clin. Invest. 122 (2012), 1339–1353.
3. Chao, E.C., Henry, R.R., SGLT2 inhibition—a novel strategy for diabetes treatment. Nat. Rev. Drug Discov. 9 (2010), 551–559.
4. Dias, V., Junn, E., Mouradian, M.M., The role of oxidative stress in Parkinson's disease. J. Parkinsons Dis. 3 (2013), 461–491.
5. Friedewald, W.T., Levy, R.I., Fredrickson, D.S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972), 499–502.
6. Han, S., Hagan, D.L., Taylor, J.R., Xin, L., Meng, W., Biller, S.A., Wetterau, J.R., Washburn, W.N., Whaley, J.M., Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57 (2008), 1723–1729.
7. Jabbour, S.A., Goldstein, B.J., Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int. J. Clin. Pract. 62 (2008), 1279–1284.
8. Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., Kim-Mitsuyama, S., Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc. Diabetol., 13, 2014, 148.
9. MacDonald, P.E., El-Kholy, W., Riedel, M.J., Salapatek, A.M., Light, P.E., Wheeler, M.B., The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51:Suppl. 3 (2002), S434–442.
10. Mather, A., Pollock, C., Glucose handling by the kidney. Kidney Int. Suppl., 2011, S1–6.
11. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
12. Min, S.H., Yoon, J.H., Hahn, S., Cho, Y.M., Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes Metab. Res. Rev., 33, 2017.
13. Naznin, F., Sakoda, H., Okada, T., Tsubouchi, H., Waise, T.M., Arakawa, K., Nakazato, M., Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. Eur. J. Pharmacol. 794 (2017), 37–44.
14. Oguma, T., Kuriyama, C., Nakayama, K., Matsushita, Y., Yoshida, K., Kiuchi, S., Ikenaga, Y., Nakamaru, Y., Hikida, K., Saito, A., Arakawa, K., Oka, K., Ueta, K., Shiotani, M., The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats. J. Pharmacol. Sci. 127 (2015), 456–461.
15. Pintana, H., Apaijai, N., Pratchayasakul, W., Chattipakorn, N., Chattipakorn, S.C., Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci. 91 (2012), 409–414.
16. Pintana, H., Apaijai, N., Chattipakorn, N., Chattipakorn, S.C., DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J. Endocrinol. 218 (2013), 1–11.
17. Pintana, H., Pongkan, W., Pratchayasakul, W., Chattipakorn, N., Chattipakorn, S.C., Dipeptidyl peptidase 4 inhibitor improves brain insulin sensitivity, but fails to prevent cognitive impairment in orchiectomy obese rats. J. Endocrinol. 226 (2015), M1–M11.
18. Pipatpiboon, N., Pratchayasakul, W., Chattipakorn, N., Chattipakorn, S.C., PPARgamma agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology 153 (2012), 329–338.
19. Pipatpiboon, N., Pintana, H., Pratchayasakul, W., Chattipakorn, N., Chattipakorn, S.C., DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. Eur. J. Neurosci. 37 (2013), 839–849.
20. Poudel, R.R., Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition. Indian J. Endocrinol. Metab. 17 (2013), 588–593.
21. Pratchayasakul, W., Kerdphoo, S., Petsophonsakul, P., Pongchaidecha, A., Chattipakorn, N., Chattipakorn, S.C., Effects of high-fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticosterone. Life Sci. 88 (2011), 619–627.
22. Pratchayasakul, W., Sa-Nguanmoo, P., Sivasinprasasn, S., Pintana, H., Tawinvisan, R., Sripetchwandee, J., Kumfu, S., Chattipakorn, N., Chattipakorn, S.C., Obesity accelerates cognitive decline by aggravating mitochondrial dysfunction, insulin resistance and synaptic dysfunction under estrogen-deprived conditions. Horm. Behav. 72 (2015), 68–77.
23. Sa-Nguanmoo, P., Tanajak, P., Kerdphoo, S., Satjaritanun, P., Wang, X., Liang, G., Li, X., Jiang, C., Pratchayasakul, W., Chattipakorn, N., Chattipakorn, S.C., FGF21 improves cognition by restored synaptic plasticity, dendritic spine density, brain mitochondrial function and cell apoptosis in obese-insulin resistant male rats. Horm. Behav. 85 (2016), 86–95.
24. Sripetchwandee, J., Pipatpiboon, N., Chattipakorn, N., Chattipakorn, S., Combined therapy of iron chelator and antioxidant completely restores brain dysfunction induced by iron toxicity. PLoS One, 9, 2014, e85115.
25. Sripetchwandee, J., Pipatpiboon, N., Pratchayasakul, W., Chattipakorn, N., Chattipakorn, S.C., DPP-4 inhibitor and PPARgamma agonist restore the loss of CA1 dendritic spines in obese insulin-resistant rats. Arch. Med. Res. 45 (2014), 547–552.
26. Verdile, G., Keane, K.N., Cruzat, V.F., Medic, S., Sabale, M., Rowles, J., Wijesekara, N., Martins, R.N., Fraser, P.E., Newsholme, P., Inflammation and oxidative stress: the molecular connectivity between insulin resistance, obesity, and Alzheimer's disease. Mediat. Inflamm., 2015, 2015, 105828.
27. Wilding, J.P., Woo, V., Soler, N.G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., Dapagliflozin 006 Study, G, Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann. Intern. Med. 156 (2012), 405–415.